Biotechnology
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced ...
2025-05-20 21:02
2041
Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC
SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety a...
2025-05-20 18:18
3233
BioFlag Showcases Innovative Probiotic Solutions at Vitafoods Europe 2025
BARCELONA, Spain, May 20, 2025 /PRNewswire/ -- BIOFLAG CO.,LTD.(Bioflag), a
leading probiotic enterprise located inChina, proudly unveiled its
scientifically validated functional probiotic solutions at Vitafoods Europe
2025, drawing high attention from global media.
2025-05-20 18:00
1396
WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories
SHANGHAI, May 19, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple top awards- "Best CEO", "Bes...
2025-05-20 09:44
2988
Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs
SUZHOU, China, May 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics....
2025-05-19 21:00
2026
TCI Biotech to Unveil New Vision at Vitafoods Europe 2025: CDMO+, High-Absorption Innovation, and 45 Years of Scientific Leadership
BARCELONA, Spain, May 19, 2025 /PRNewswire/ -- TCI Biotech, a global leader in health and wellness innovation, will mark a major milestone at Vitafoods Europe 2025 with a dynamic showcase of its rebranded identity, next-gen CDMO+ model, and advanced nutritional technologies. Located at booth #3G6...
2025-05-19 16:00
1653
2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH
——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals("CureGene") ...
2025-05-17 08:41
3851
SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment
TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will d...
2025-05-16 23:10
4335
Visionary: Pioneering a New Era in Cancer Screening
TORONTO, May 16, 2025 /PRNewswire/ -- Recently, Visionary has achieved a significant breakthrough in the field of early cancer screening and home self - testing technologies, attracting widespread attention from the industry. American Precision Biotech Inc. is a subsidiary of Visionary Holdings. ...
2025-05-16 21:30
2603
Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment
HONG KONG, May 15, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor ne...
2025-05-16 11:57
2042
Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences
* The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy will be presented orally at the 2025 ICML * A pooled safety and efficacy analysis of two Phase I/II studies ...
2025-05-15 18:09
2319
Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery
HONG KONG, May 15, 2025 /PRNewswire/ -- Artificial intelligence has rapidly evolved from academic theory into a transformative force in pharmaceutical R&D. From early QSAR models to neural networks, and now to AlphaFold3, AI has progressively unlocked deeper biological insights. By integrating st...
2025-05-15 15:02
2129
Tsingke Showcases at AACR 2025 -- Advancing Global Cancer Research with Integrated Synthesis Solutions
BEIJING, May 15, 2025 /PRNewswire/ -- Tsingke Biotech proudly participated in theAACR Annual Meeting 2025, held this April in Chicago, USA. As one of the world's premier events in oncology research, AACR gathered global leaders from academia and industry to explore the future of cancer diagnostic...
2025-05-15 14:12
1861
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
— Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration BRUSSELS, May 15, 2025 /PRNewswire/ -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international ...
2025-05-15 13:04
1764
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat
* Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. * The company has received the EOP2 meeting minutes, confirming the primar...
2025-05-14 13:38
1830
GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California
YONGIN, South Korea, May 14, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that its U.S. subsidiary, ABO Holdings, has received FDA approval for its plasma collection center located inCalexico, California. Following the successful U.S. launch of ALYGLO (im...
2025-05-14 13:21
1922
iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization
* Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections * Demonstrated its Efficacy and Safety through previous Clinical Trials * Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotech...
2025-05-13 20:00
1698
Hyundai ADM Bio Voluntarily Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy
Declares a strategic pivot to lead the post-patent immunotherapy combination era SEOUL, South Korea, May 13, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) today announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating...
2025-05-13 19:47
1799
Strategic Partnership | Sanyou Bio and TransRecoBio Forge Strategic Alliance to Build a New Ecosystem for the Full Industry Chain
SHANGHAI, May 13, 2025 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals ( Shanghai) Co., Ltd. ("Sanyou Biopharmaceuticals") and TransRecoBio (Wenzhou) Biotechnology Co., Ltd. ("TransRecoBio") officially signed a strategic cooperation agreement. The two companies will integrate their core streng...
2025-05-13 18:00
2104
GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy
* GI Innovation and GI Biome have been selected as a Top 40 semi-finalist in the XPRIZE Healthspan competition among 600 registered teams from 58 countries * Selected as one of 8 teams to pitch at the XPRIZE Investor Summit in New York * The team is now competing for one of the largest prize...
2025-05-13 09:21
1917
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00